Overview
Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)
Status:
Completed
Completed
Trial end date:
2013-06-01
2013-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a strain of Respiratory Syncytial Virus.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Gilead SciencesTreatments:
Pharmaceutical Solutions
Criteria
Inclusion Criteria:- Healthy male or female
- Between 18 to 45 years old
- Body Mass Index of 18 to 33 kg/m2
Exclusion Criteria:
- Acute or chronic medical illness
- Positive for Human Immunodeficiency Virus, Hepatitis B or C
- Nose or nasopharynx abnormalities
- Abnormal lung function